Rybelsus or oral Wegovy for weight loss: which is authorised for weight management, how they differ and what they cost

If you're looking into Rybelsus for weight loss, the first thing to know is that Rybelsus is only indicated for type 2 diabetes, so using it to lose weight is off-label. The oral semaglutide that is authorised for weight management in Spain is Wegovy tablets, which is approved for obesity and for overweight with at least one related condition. Both contain the same molecule, but they differ in indication, maximum dose, what their trials measured, price and funding.

What is each one indicated for?

According to its summary of product characteristics (SmPC), Rybelsus is used in adults with poorly controlled type 2 diabetes to improve blood glucose control, alongside diet and exercise. It can be used on its own when metformin is not suitable, or in combination with other antidiabetic drugs. Obesity and weight management are not listed as indications in the SmPC.

Wegovy tablets has a different indication: weight management, covering both weight loss and keeping the weight off, as an adjunct to a reduced-calorie diet and increased physical activity. It is intended for adults with a BMI of 30 or more, or from 27 to under 30 if they have at least one weight-related condition, such as prediabetes or type 2 diabetes, high blood pressure, abnormal cholesterol or triglyceride levels, sleep apnoea or cardiovascular disease. The SmPC has no data in people under 18.

The European Commission authorised Wegovy tablets in July 2026 (Novo Nordisk announced it on the 15th), and CIMA, the medicines database of the Spanish Agency of Medicines and Medical Devices (AEMPS), records the authorisation on 22 July. CIMA currently lists all four strengths as marketed in Spain: 1.5, 4, 9 and 25 mg. Someone with type 2 diabetes and obesity may fit both indications; someone without diabetes fits only the Wegovy indication.

Why does the same molecule have two different names?

Rybelsus and Wegovy tablets are both semaglutide, the same active substance as in Ozempic and injectable Wegovy, and Novo Nordisk holds the marketing authorisation for both. What sets them apart is the dossier on which each medicine was authorised. Rybelsus was studied in the PIONEER trials, in people with type 2 diabetes, with blood glucose control as the primary endpoint. Wegovy tablets was studied in the OASIS 4 trial, in people with obesity or overweight without diabetes, with weight loss as the endpoint. Each product's indication reflects what was shown in its own trials.

There's one detail that confuses a lot of people. In February 2026 the AEMPS announced that Rybelsus was moving to a new, better-absorbed formulation: the 3 mg tablet became 1.5 mg, the 7 mg became 4 mg and the 14 mg became 9 mg, with the same efficacy and safety. That's why many older articles refer to Rybelsus 14 mg, which is no longer marketed. The new Rybelsus strengths match the first three Wegovy tablet strengths in milligrams, yet they remain different medicines.

What is the maximum authorised dose of each?

What follows is what each SmPC states, not a dosing plan: the dose is decided by the prescribing doctor. The Rybelsus SmPC starts at 1.5 mg a day for one month and then increases to 4 mg; from there, if needed, the dose moves up to the next step after at least one month on each. Its maintenance doses are 4, 9, 25 and 50 mg, and the maximum daily dose is 50 mg. In Spain, however, CIMA only lists the 1.5, 4 and 9 mg presentations: the 25 and 50 mg strengths do not appear, so the highest strength that can be dispensed here is 9 mg.

The Wegovy tablets SmPC starts at 1.5 mg a day for four weeks and steps up to 4, 9 and 25 mg, with at least four weeks at each step. The 25 mg dose is both the maintenance dose and the maximum. For both medicines, the SmPC says to take a single tablet a day and not to take several tablets to reach a higher dose. Both SmPCs describe the same way of taking it: after fasting for at least 8 hours, swallowed whole with a sip of water of up to 120 ml, then waiting at least 30 minutes before eating, drinking or taking other medicines, because waiting less reduces absorption.

How much weight was lost in each product's trials?

OASIS 4, the Wegovy tablets trial, enrolled 307 adults with obesity, or with overweight and at least one comorbidity, and without diabetes. At 64 weeks, body weight fell on average by 13.6% with oral semaglutide 25 mg versus 2.2% with placebo; in kilos, 14.2 kg versus 2.2 kg, from a starting weight of around 106 kg. That is the figure in the SmPC and in the NEJM, and it counts all participants. Novo Nordisk reports a figure of around 17%, but that applies only to those who stayed on treatment.

In PIONEER 1, one of the Rybelsus trials, 703 people with type 2 diabetes took the drug or placebo for 26 weeks. On 14 mg, the old strength equivalent to today's 9 mg, weight fell by 3.7 kg versus 1.4 kg with placebo, from a starting weight of around 88 kg. In PIONEER PLUS, a 52-week trial also in type 2 diabetes, weight loss was 4.4 kg on 14 mg, 6.7 kg on 25 mg and 8.0 kg on 50 mg, from around 96 kg. In these trials weight was a secondary outcome: the main aim was to lower blood glucose.

The figures can't be compared head to head: the populations, durations and doses differ, and no trial has pitted the two medicines against each other. The Wegovy tablets SmPC itself warns that people with diabetes are expected to have lower exposure to the drug and to lose less weight than people without diabetes. What happens when you stop treatment is another question worth asking before you start, and we cover it in regaining weight after stopping treatment.

How much do they cost, and which one does Spain's National Health System fund?

Rybelsus has an official price in the Spanish Ministry of Health's Nomenclátor: €123.53 for a box of 30 tablets, the same for 1.5, 4 and 9 mg. At one tablet a day, a box lasts 30 days. According to BIFIMED, the National Health System (SNS) funds it, subject to prior authorisation (visado), only in type 2 diabetes with a BMI of 30 or more and in combination with other antidiabetic drugs, not when taken on its own. Outside those conditions it isn't funded and the patient pays the full cost. The breakdown by strength and per month is in the price of Rybelsus in Spain.

Wegovy tablets has no published official price, because it isn't funded and its price is set freely. Press reports put the box of 30 × 25 mg tablets at €236.20, roughly €236 a month; the price of the starting doses has not been published. BIFIMED lists it as not funded from 1 September 2026, for both obesity and overweight with comorbidity. It requires a doctor's prescription and you pay the full price at the pharmacy. We break down how that fits with the rest of the cost in how much medical weight loss treatment costs.

Can you switch from Rybelsus to Wegovy, or the other way round, on your own?

No. They are different medicines, with different indications, dose steps and prescriptions, and any switch has to be decided and prescribed by a doctor. When Rybelsus changed formulation, the AEMPS already warned that mixing up presentations can lead to medication errors, with greater exposure to semaglutide and more digestive side effects such as nausea, vomiting or diarrhoea. That's why a prescription for the old presentations isn't valid for the new ones.

The Wegovy tablets SmPC adds that semaglutide should not be used with other GLP-1 receptor agonists, because this has not been studied and a higher risk of adverse effects from overdose is considered likely. Taking both at once, or topping one up with tablets of the other, is exactly what to avoid. And matching milligrams don't make two medicines authorised for different purposes interchangeable.

If you already take Rybelsus, see how the new strengths correspond to the old ones. And to see all the oral options side by side, there's our guide to prescription weight loss pills.

On taking Wegovy tablets each day, how to take them explains the fasting and water requirements, and their side effects covers what is known about how well they are tolerated.

Key takeaways

Rybelsus is oral semaglutide for type 2 diabetes; Wegovy tablets is the oral semaglutide indicated for obesity, with its own maximum dose, its own trial and its own price. Choosing between them isn't a matter of preference but of diagnosis, and that is for a doctor to assess with your medical history in front of them. What is available in Spain today for anyone who wants to lose weight with medical support is medical weight loss treatment with an initial assessment, prescription where appropriate by a registered doctor, and ongoing follow-up. You can:

Check in a few minutes whether you're eligible